» Articles » PMID: 32656988

Unexpected Favorable Outcome to Sintilimab Plus Bevacizumab in an EGFR-mutated Non-small Cell Lung Cancer Patient: A Case Report

Overview
Journal Thorac Cancer
Date 2020 Jul 14
PMID 32656988
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

A 53-year-old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first-line setting. After disease progression, he received targeted therapy because of subsequent detection of EGFR exon 19 del mutation. Following an increase in his adrenal metastases, a combination of immunotherapy and antiangiogenic therapy (sintilimab plus bevacizumab) was commenced. After one month, imaging showed that the adrenal metastases had shrunk and a progression-free survival (PFS) of 6.0 months was achieved. In this case, we showed that the PD1 inhibitor sintilimab plus bevacizumab was effective in a refactory advanced EGFR-mutant NSCLC with positive PD-L1 expression. KEY POINTS: Our case report provides clinical evidence of the durable response of a patient with advanced EGFR-mutant lung adenocarcinoma to a combination of immunotherapy and anti-angiogenic agent, sintilimab and bevacizumab, as subsequent-line therapy. Sintilimab and bevacizumab combination therapy was well-tolerated and effective, resulting in dramatic tumor reduction and improvement in clinical symptoms.

Citing Articles

Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.

Wan C, Zhang Y, Liu P, Mei X, Cheng G, Pang J J Thorac Dis. 2023; 15(10):5648-5657.

PMID: 37969256 PMC: 10636450. DOI: 10.21037/jtd-23-1399.


[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer 
with EGFR Mutation].

Zhu Y, Dai Z Zhongguo Fei Ai Za Zhi. 2022; 25(10):742-749.

PMID: 36167460 PMC: 9619349. DOI: 10.3779/j.issn.1009-3419.2022.101.44.


Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.

Ai Q, Chen W, Li Y, Li G Front Immunol. 2022; 13:840916.

PMID: 35720298 PMC: 9204206. DOI: 10.3389/fimmu.2022.840916.


Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.

Li Y, Zhou Y, Liu Y, Zhang G, Xiao L, Li N Thorac Cancer. 2021; 12(11):1780-1783.

PMID: 33949137 PMC: 8169295. DOI: 10.1111/1759-7714.13967.


The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.

Zhai C, Zhang X, Ren L, You L, Pan Q, Pan H Front Oncol. 2021; 10:619010.

PMID: 33680942 PMC: 7927598. DOI: 10.3389/fonc.2020.619010.


References
1.
Zhou Z, Zhan P, Song Y . PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015; 4(2):203-8. PMC: 4384212. DOI: 10.3978/j.issn.2218-6751.2015.03.02. View

2.
Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

3.
Zou H, Li Q, Lee J, Arango M, McDonnell S, Yamazaki S . An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67(9):4408-17. DOI: 10.1158/0008-5472.CAN-06-4443. View

4.
Manegold C, Dingemans A, Gray J, Nakagawa K, Nicolson M, Peters S . The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2016; 12(2):194-207. DOI: 10.1016/j.jtho.2016.10.003. View

5.
Nagano T, Tachihara M, Nishimura Y . Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells. 2018; 7(11). PMC: 6262543. DOI: 10.3390/cells7110212. View